The approval makes IBA the first company with a cyclotron-based proton therapy system to receive FDA approval for PBS.
IBA claims its technology allows physicians to more precisely control the dosage and targeting of a proton beam, which reduces the harm caused to healthy tissues.
Pierre Mottet, IBA's CEO, said: “This approval is a significant step forward in ensuring that proton therapy continues to advance and employ the most innovative and effective treatment modes available.
“Proton therapy professionals and their patients will now be able to experience firsthand the myriad therapeutic benefits of employing PBS technology to combat cancer”.
The technology has already been adopted by some hospitals, including the Francis H Burr Proton Therapy Center which collaborated with IBA on PBS’ development.
PBS is one of four treatments that use IBA’s Universal Nozzle, which the company claims gives physicians flexibility in their treatment of cancer.
In addition to PBS the Universal Nozzle is used for uniform scanning and double and single scattering delivery methods.
New facilities, new markets
The FDA’s approval follows IBA’s setting up of a new facility in Dallas, Texas and the establishment of a Memorandum of Understanding with South Korean firm Hae Dong.
Following the completion of the new facility IBA now has 47 distribution centres, 17 of which are located in the US. Through the deal with Hae Dong IBA gained seven facilities in South Korea and strengthened its presence in the Asian market.